Study finds early pancreatic cancer staging often inaccurate

Apel­lis Phar­ma­ceu­ti­cal’s pegc­eta­coplan has shown hints of ef­fi­ca­cy in a hand­ful of pa­tients with rare kid­ney dis­eases in a Phase II tri­al, five months af­ter

A drug engineered to “digest” extracellular RNA missed its primary endpoint in an early-stage clinical trial in systemic lupus erythematosus (SLE), though patients with higher